Oxybutynin Extended Release vs. Tolterodine Immediate Release for Overactive Bladder in the UK: Economic Analysis
Getsios D1, Caro J1, Ishak J1, El-Hadi W1, Payne K1, O'Connel M2, Albrecht D2, Dubois D3, Feng W3 1. Caro Research Institute, 2. ALZA Corporation, 3. Johnson & Johnson Pharmaceutical Services, LLC
Abstract Category
Reconstructive Surgery: LUT
|
|
Abstract 369
|
|
|
Non Discussion Posters
Scientific Non Discussion Poster Session 16
|
|
|